RT-PCR analysis of IL-6, IL-8, and VEGF mRNA expression in HIOEC cells stimulated with imiquimod (1 μg/ml) for indicated time points.
Introduction
The prognosis of human oral squamous cell carcinoma (OSCC) is usually poor with a 5-year survival rate. [1] [2] Recently, there has been an increasing interest in anti-tumor functions introduced by the innate immune response. The role of toll-like receptors (TLRs) and their signaling in tumor immune escape and resistance to apoptosis is among the frontiers of exploration. [3] [4] [5] [6] Toll-like receptors (TLRs) were primarily discovered in drosophila, in the membranes of binding pattern recognition receptors (PRRs) and were recognized as targeting a series of mechanisms causing synthesis and secretion of cytokines and activating other host defense programs, critical for initiation of innate or adaptive immunity. [7] [8] [9] [10] Recently, it is reported that most mammalian species have 10 to 15 types of TLRs. Thirteen TLRs (TLR1 to TLR13) have been recognized in human and mice. [8] [9] [10] [11] The extracellular domains of TLR comprise [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] LRRs that involve some physiologic functions. [12] [13] [14] TLRs 3, 7, 8 and 9 are entirely localized to intracellular membranes where they are preferably positioned for activation by nucleic acids of bacterial and viral origin. [8, 10] Some researchers have been reviewed TLR signaling pathways during pathogen recognition. They have described the induction of immune reactions by means of extracellular and intracellular pathways mediated by myeloid differentiation factor 88 (MyD88), nuclear factor kappa-light-chain-enhancer of activated B cells, and mitogen-associated protein kinase (MAPK). [15] [16] The MyD88-independent pathway is mediated by TIR-domain-containing adapter-inducing interferon-β (TRIF). TLR3 and TLR4 use TRIF to activate interferon-regulated factor 3 (IRF3).
Activation of IRF3 results in production of INF-β. [17] [18] Finally, the activation of TRIF-related adaptor molecule (TRAM) is TLR4-induced and results in TRIF employment. TRAM localized to late endosomes where TAG prevents IRF3 activation and inflammatory cytokine production is prompted by TLR2, TLR7 and TLR9 ligands. Phosphorylation and nuclear translocation of IRF3 can present TBK1 or IKKi/IKK. TLR7 mediates anti-viral immunity by identifying ssRNA viruses. [11] Small molecular weight TLR7 agonists have already been accepted, or are still being assessed, for treatment of cancers or infectious diseases. [12] The proximal region of this promotor drives the transcription of the TLR7 gene. Pro-inflammatory stimuli starts TLR7 transcription by means of a MAPK binding in this region, and this instigation might be impeded by mutation of the MAPK binding site or addition of MAPK inhibitors.
The purpose of this study was to determine MAPK activation dependent TLR7 in HIOEC cell lines of OSCC.
Materials and Method

Cell lines
The HIOEC cell line was obtained from the Creative Bioarray Company. HIOEC is human immortalized oral epithelial cells, attained from normal oral mucosa immortalized by transfection of HPV16 E6/E7 gene. HI-OEC cells were sustained in defined keratinocyte serum-free medium (Gibco, NY, USA) and normal cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (Gibco; NY, USA). Moreover, the normal oral epithelial cells were obtained from patients who undergone third molar surgeries referred to private clinic. Written informed consents were provided from all participants. All cells were cultured in a humidified atmosphere of 5% CO2 at 37°C. Imiquimod was obtained from Sigma (MO, USA), and p38 specific inhibitor PD169316 was purchased from Abcam (MA, USA). 
Conclusion
The current study indicated that TLR7 was functionally over-expressed in human OSCC cells and development of resistance to cisplatin in human OSCC might occur through the mechanism involving activation of TLR7
and its signaling pathway. Thus, suppression of TLR7
and its signaling pathway might elevate sensitivity to cisplatin and potentially improve the prognosis of patients with OSCC.
